London

Boots launches on-demand delivery trial with Deliveroo

Customers can order medicines for mild ailments, makeup, toiletries and more from 14 stores The pharmacy chain Boots will become the latest large retailer to make its products available through Deliveroo, as the takeaway delivery company aims to expand beyond restaurant orders. Stores in London, Birmingham, Edinburgh and Nottingham will be among the 14 initially …

Boots launches on-demand delivery trial with Deliveroo Read More »

Eli Lilly’s $15M investment deepens link to startup developing new class of RNA meds

Two months after Eli Lilly began an alliance with MiNA Therapeutics, a startup developing a new type of RNA therapy, the pharmaceutical giant is making a $15 million equity investment in its partner. MiNA is developing a new class of medicines called small activating RNA therapies.

Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors

The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.

London’s digital health accelerator programme selects 20 new projects

DigitalHealth.London has announced the latest 20 small and medium sized businesses selected for its digital accelerator programme. The programme selects digital solutions or services with the highest potential to meet the city’s health and social care challenges. This the fifth year the event has been running and the NHS delivered programme will see funding matched …

London’s digital health accelerator programme selects 20 new projects Read More »

Report: FDA takes closer look at adverse event that occurred in AstraZeneca Covid-19 vaccine study

Reuters reported Wednesday that U.S. regulators would look at data from previous clinical trials that came from the same scientists who created the vaccine, AZD1222, which originated at the University of Oxford and is also known as ChAdOx1 nCoV-19.

AstraZeneca starts Phase I study of long-acting double-antibody cocktail for Covid-19

The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and health authorities in the U.S., is enrolling up to 48 healthy volunteers in the U.K. AstraZeneca’s double-antibody approach is similar to that of Regeneron and Roche with their drug, REGN-COV2.

GSK nabs FDA approval for first-in-class multiple myeloma drug

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.

AstraZeneca, Daiichi Sankyo sign $6B deal for antibody-drug conjugate

The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.

Russian hackers suspected in Covid-19 vaccine intellectual property theft, report says

A joint report by cybersecurity agencies in the U.K. and Canada, endorsed by their U.S. counterparts, states that the hacker group Cozy Bear had been targeting organizations involved with Covid-19 vaccine development efforts.

FDA AdCom votes unanimously in favor of GSK myeloma drug, despite earlier agency skepticism

The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the FDA in briefing documents ahead of the ODAC meeting, particularly with regard to ocular toxicity.

FDA raises concerns over ocular toxicity from GSK’s potential first-in-class myeloma drug

The FDA’s Oncologic Drugs Advisory Committee will convene Tuesday to discuss the drug, belantamab mafodotin. Despite the drug’s first-in-class potential, the briefing document for the meeting raised concerns about eye toxicity and questions about its risk-benefit profile.

ViiV’s twice-monthly injected PrEP drug superior in HIV prevention to Gilead daily pill, analysis shows

The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.